Goutham Sunny Highlighted PANOVA-3 Phase III Trial on TTFields Plus Chemotherapy in Locally Advanced Pancreatic Cancer
Goutham Sunny, Former Resident Doctor at The Gujarat Cancer and Research Institute, shared a post on X։
“PANOVA-3 Phase III Breakthrough
In unresectable locally advanced pancreatic cancer (LA-PAC), adding Tumor Treating Fields (TTFields) to gemcitabine + nab-paclitaxel offers meaningful clinical gains.
Key Results:
– OS ↑: 16.2 vs 14.2 mo (HR 0.82, P=.039)
– Pain-free survival ↑: 15.2 vs 9.1 mo (P=.027)
– Distant PFS ↑: 13.9 vs 11.5 mo (P=.022)
– No gain in ORR, PFS, or local controlSide Effects:
– Device-related skin AEs in 76.3% (mostly mild/moderate)
– Grade 3 skin AEs in 7.7%
– No added systemic toxicityWhy It Matters:
– First positive phase III trial in LA-PAC in years
– Non-invasive TTFields improve survival endpoints
– Requires patient adherence to device use
– Suggests new non-chemotherapy mechanism to enhance outcomesTTFields + chemo = new frontier in pancreatic cancer care.”
Title: Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study
Journal: JCO
Authors: Hani M. Babiker, Vincent Picozzi, Sreenivasa R. Chandana, Bohuslav Melichar, Anup Kasi, Jin Gang, Javier Gallego, Andrea Bullock, Hao Chunyi, Lucjan Wyrwicz, Erika Hitre, Arsen Osipov, Christelle de la Fouchardiere, Inmaculada Ales, Tomislav Dragovich, Woojin Lee, Kynan Feeney, Philip Philip, Makoto Ueno, Eric Van Cutsem, Thomas Seufferlein, Teresa Macarulla
More posts featuring Goutham Sunny on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023